Biomedical Occupation or Discipline
Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb
Harbour BioMed; Bristol Myers Squibb; BMS; multi-specific antibodies; $90 million upfront; $1.035 billion milestones; global strategic collaboration; license agreement; Harbour Mice technology; immunology; oncology; biobucks deal; China early clinical trials
GSK wins FDA approval for ultra-long-acting asthma drug Exdensur (depemokimab)
GSK; Exdensur; depemokimab; FDA approval; severe asthma; ultra-long-acting biologic; twice-yearly dosing; type 2 inflammation; eosinophilic phenotype; IL-5 inhibitor
Specific Biologics Appoints Dr. Richard Glickman to Board of Directors
Specific Biologics; Richard Glickman; Board of Directors; biotechnology; genome editing
Sanofi returns to Dren Bio for another B‑cell depletion therapy with $100M upfront
Sanofi; Dren Bio; B-cell depletion; autoimmune diseases; strategic collaboration; bispecific antibody; myeloid cell engager; immunology; $100M upfront; licensing deal
Ankyra Therapeutics Appoints Sailaja Battula, PhD as Chief Scientific Officer
Ankyra Therapeutics; Sailaja Battula; CSO appointment; immuno-oncology; biotechnology
CDC highlights strong effectiveness of 2024–2025 COVID-19 shots in kids while FDA reviews reports of alleged post-vaccination deaths
CDC; FDA; COVID-19 vaccine; children; pediatrics; vaccine effectiveness; emergency department visits; urgent care visits; safety review; alleged deaths; VAERS
Ventus Therapeutics Doses First Patient in Phase 2 Trial of VENT-03, an Oral cGAS Inhibitor, in Lupus
Ventus Therapeutics; VENT-03; cGAS inhibitor; Phase 2 trial; lupus; cutaneous lupus erythematosus; autoimmune disease; interferon pathway; biomarkers; oral small molecule; clinical trial; immunology; cardiometabolic; inflammaging
Mindpeak Secures First Patent for Advanced AI Method in Digital Pathology
Mindpeak; digital pathology; AI-powered pathology; oncology diagnostics; cell classification; histopathology; EU patent; United Kingdom validation; AI model training; precision diagnostics
Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment
Pluri; Alejandro Weinstein; Chairman of the Board; strategic shift; additional investment; ownership increase; Zami Aberman; Vice Chairman; biotechnology; healthcare; M&A transactions; value creation; commercialization; corporate governance
PathAI’s AIM-MASH AI Assist Receives Historic FDA Qualification for MASH Clinical Trials
PathAI; AIM-MASH; AI Assist; FDA qualification; Drug Development Tool; biomarker qualification; MASH; MASLD; NASH; metabolic dysfunction-associated steatohepatitis; AI pathology; clinical trials; EMA qualification; liver biopsy; histology